J.F. Seitz
Aix-Marseille Université · 43 works · 470 citations · h-index 10
Top works
- BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
- Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone
- 1086 Cetuximab in a randomized phase II trial as a single agent or in combination with irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing, irinotecan-refractory metastatic colorectal cancer (CRC)
- Efficacy and safety of sorafenib in patients with alcohol-related hepatocellular carcinoma: A sub-analysis from the SHARP trial
- ‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’
- Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting
- Relation between endoscopic ultrasound evaluation and survival of patients with inoperable thoracic squamous cell carcinoma of the oesophagus treated by combined radio- and chemotherapy.
- Efficacy of prophylactic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancer.
- 701 ‘Tomudex’ (ZD1694) has a higher response rate, significantly less leucopenia and mucositis and a simpler dosing regimen than 5-fluorouracil (5-FU) and leucovorin (LV) for advanced colorectal cancer (CRC): First results of a phase III study
- 2139 CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy
- Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI).
- Que faire devant un cancer digestif en 1999? Recommandations de la Fondation Française de Cancérologie Digestive (1re partie).
- Efficacy of 5FU + cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC)
- Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)
- Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m)
- 292 Tegafox, a new combination of UFT/LV and oxaliplatin as first line treatment for patients (pts) with non resectable metastatic colorectal cancer (CRC): results of a completed multicenter phase II
- [Immunotherapy of colorectal cancers].
- Thymidylate synthase (TS) and P53 expression predict event-free survival (EFS) but not the response to adjuvant chemotherapy of patients with colonic carcinoma (CC)
- Results of the Phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib and pravastatin vs best supportive care for the palliative treatment of HCC in CHILD B cirrhotic patients
- Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial